PEGylation of microspheres for therapeutic embolization: preparation, characterization and biological performance evaluation.
In this study, microspheres designed for embolization, defined as GF2000-Trisacryl MS (GF-MS) and DEAE-Trisacryl MS (DEAE-MS), were originally PEGylated using (3-amino propyl) triethoxy silane as coupling agent. Indomethacin was loaded into both PEGylated and non-PEGylated DEAE-MS, displaying ion-exchange ability, through a batch process with a respective capacity of 1.2 and 0.25 g/g. The morphology of naked and PEGylated MS was evaluated by scanning electron microscopy (SEM). Both micosphere resins surface looked like orange skin, although DEAE-MS showed a slightly rougher surface due to the copolymerization process. PEGylated microspheres have a most likely swelling surface owing to the presence of PEG hydrophilic chains. The mean diameters were of about 66 and 60 microm for GF-MS and DEAE-MS, respectively. Data obtained for PEGylated MS by Fourier Transform Infrared spectroscopy (FTIR) confirmed that microspheres were successfully PEGylated. Finally, complement activation in vitro was performed to evaluate the activating capacity of different microspheres. Both PEGylated GF-MS and DEAE-MS activated the complement system of about 33% less than their corresponding naked microspheres, while loading PEGylated DEAE-MS with indomethacin almost suppressed complement activation. This inhibiting role implies that PEGylation as well as loading the microspheres with anti-inflammatory drug has a compact effect on the interaction of microspheres with blood proteins.
Madani
Faten
F
Laboratoire de Pharmacie Galénique, Faculté de Siences Pharmaceutiques et Biologiques, Université Paris 5, 4 avenue de l'observatoire, 75270 Paris Cedex 06, France. fatenmadani@yahoo.fr
Bessodes
Michel
M
Lakrouf
Amina
A
Vauthier
Christine
C
Scherman
Daniel
D
Chaumeil
Jean-Claude
JC
D001672:Biocompatible Materials / Q000737:chemistry*; D003167:Complement Activation / Q000187:drug effects* / Q000502:physiology*; D004621:Embolization, Therapeutic / Q000379:methods*; D006801:Humans; D008422:Materials Testing; D010316:Particle Size; D011092:Polyethylene Glycols / Q000737:chemistry* / Q000627:therapeutic use*; D013499:Surface Properties
D001672:Biocompatible Materials; D011092:Polyethylene Glycols